Sichuan Huiyu Seacross Pharma Technology Ltd.

The main purpose of dose escalation is to evaluate the safety and tolerability of HY07121 for injection in the treatment of patients with advanced malignant solid tumors; to explore the maximum tolerated dose (MTD) and provide a recommended dose (RP2D) and a reasonable dosing regimen for Phase II or subsequent clinical studies. The main purpose of dose expansion is to evaluate the anti-tumor efficacy of HY07121 for injection.

Dose escalation: Primary objective: To evaluate the safety and tolerability of HYP-2090PTSA in patients with advanced solid tumors with KRAS mutations; To determine the recommended phase II dose (RP2D) and/or maximum tolerated dose (MTD) of HYP-2090PTSA. Dose expansion: Primary objective: To evaluate the efficacy of HYP-2090PTSA in patients with advanced solid tumors with KRAS G12C mutations.

The main purpose of the study is to compare the pharmacokinetic characteristics of the ferric carboxymaltose injection (10mL: 500mg (in terms of iron)) provided by Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. and the ferric carboxymaltose injection (trade name: Ferinject®, specification: 10mL: 500mg (in terms of iron)) held by Vifor France in subjects with iron deficiency anemia under fasting conditions, and to preliminarily evaluate the bioequivalence of the two preparations. The secondary purpose of the study is to evaluate the safety of the ferric carboxymaltose injection (10mL: 500mg (in terms of iron)) provided by Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. under fasting conditions.